BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23589175)

  • 1. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
    Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
    Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romidepsin: in the treatment of T-cell lymphoma.
    Yang LP
    Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
    Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD
    Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
    Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
    Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
    Sager PT; Balser B; Wolfson J; Nichols J; Pilot R; Jones S; Burris HA
    Cancer Med; 2015 Aug; 4(8):1178-85. PubMed ID: 25914207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
    Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
    J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
    Bates SE; Zhan Z; Steadman K; Obrzut T; Luchenko V; Frye R; Robey RW; Turner M; Gardner ER; Figg WD; Steinberg SM; Ling A; Fojo T; To KW; Piekarz RL
    Br J Haematol; 2010 Jan; 148(2):256-67. PubMed ID: 19874311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
    Rivers ZT; Oostra DR; Westholder JS; Vercellotti GM
    J Oncol Pharm Pract; 2018 Jan; 24(1):56-62. PubMed ID: 27708192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
    Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
    Jain N; Odenike O
    Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
    Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
    Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma.
    Hronek J; Reed M
    Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin for cutaneous T-cell lymphoma.
    Prince HM; Dickinson M
    Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
    J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.